- Home
- XERS vs VTOL Comparison
XERS vs VTOL Comparison
Compare XERS & VTOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | VTOL |
|---|---|---|
| Founded | 2005 | 1948 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | XERS | VTOL |
|---|---|---|
| Price | $10.51 | $40.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $12.86 | ★ $64.33 |
| AVG Volume (30 Days) | ★ 2.3M | 198.3K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 1.23% |
| EPS Growth | ★ 100.00 | 34.58 |
| EPS | N/A | ★ 1.14 |
| Revenue | $49,590,000.00 | ★ $1,490,512,000.00 |
| Revenue This Year | $32.91 | $12.15 |
| Revenue Next Year | $23.75 | $5.89 |
| P/E Ratio | ★ N/A | $35.65 |
| Revenue Growth | ★ 142.67 | 5.30 |
| 52 Week Low | $5.25 | $35.03 |
| 52 Week High | $10.35 | $50.38 |
Technical Indicators
Market Signals| Indicator | XERS | VTOL |
|---|---|---|
| Relative Strength Index (RSI) | 69.93 | 38.11 |
| Support Level | $7.15 | N/A |
| Resistance Level | N/A | $44.07 |
| Average True Range (ATR) | 0.52 | 1.06 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 99.03 | 29.53 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About VTOL Bristow Group Inc.
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers are in the UK, Norway, the USA, Nigeria, and Others. The offshore energy customers use services to transport personnel to, from and between offshore energy installations. The majority of revenue is generated from Offshore Energy Services.